IPF / ILD Working Group



  • Luca Richeldi – Lead
  • Katerina Antoniou
  • Arata Azuma
  • Jürgen Behr
  • Demosthenes Bouros
  • Kevin Brown
  • Harold Collard
  • Tamera Corte
  • Ulrich Costabel
  • Ian Glaspole
  • Vincent Cottin
  • Bruno Crestani
  • Kevin Flaherty
  • Michael Keane
  • Gisli Jenkins
  • Martin Kolb
  • Toby Maher
  • Fernando J. Martinez
  • Mariano Mazzei
  • Ferran Morell
  • Maria Molina
  • Steven Nathan
  • Christopher Ryerson
  • Ganesh Raghu
  • Paola Rottoli
  • Moises Selman
  • Carlo Vancheri
  • Athol U. Wells
  • Thomas Geiser
  • Joan Soriano


The last meeting took place during ERS 2017 in Milan.

Work Plan

The IPF (Idiopathic Pulmonary Fibrosis) / ILD (Interstitial Lung Disease) Working Group believe that the introduction of licensed therapies for IPF place increasing emphasis on the need for earlier and more accurate diagnosis. The group believes there is a need to better understand current practice, (i.e. what is happening in the real-world) with a view to introducing appropriate treatments early to optimize potential therapeutic benefit and that these studies involve characterising real-world clinical practice and evaluating effectiveness (not drug efficacy).

Working Group Documents

File Sharing

Click here to access files available from the IPF/ILD Working Group

Useful Links

An American Thoracic Society Official Research Statement: Future Directions in Lung Fibrosis Research